Company intelligence / Profile preview
MBQ Pharma
- Ownership
- Private
- Development stage
- Other
Overview
Lead candidate MBQ‑167 targets metastatic cancers via dual Rac/CDC42 inhibition; now in Ph I trial for advanced breast cancer with promising preclinical data across several solid tumor types and immune/fibrotic disorders.
- Therapeutic areas
- OncologyImmunologyRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on MBQ Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBQ Pharma.